Ibrutinib-associated sever skin toxicity: A case of multiple inflamed skin lesions and cellulitis in a 68-year-old male patient with relapsed chronic lymphocytic leukemia – Case report and literature review.

Introduction: Ibrutinib is an oral inhibitor of Bruton's tyrosine kinase that is used for a variety of B cell hematological malignancies. Skin and subcutaneous tissue manifestations have been reported and were witnessed in up to 32% of the patients on ibrutinib. The mechanism in which ibrutinib can...

Descripción completa

Detalles Bibliográficos
Publicado en:Journal of Oncology Pharmacy Practice Vol. 26; no. 2; pp. 487 - 492
Autores principales: Ghasoub, R, Albattah, A, Elazzazy, S, Alokka, R, Nemir, A, Alhijji, I, Taha, R
Formato: case study pictorial tables/charts Journal Article
Publicado: Sage Publications Inc. Mar2020
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=141717391&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 141717391
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        10781552
        0JI
      jtl: Journal of Oncology Pharmacy Practice
      issn: 10781552
      maglogo: Y
    pubinfo:
      dt: Mar2020
      vid: 26
      iid: 2
      pid: 344
      pub: Sage Publications Inc.
      place: Thousand Oaks, California
    artinfo:
      ui:
        141717391
        141717391
        141717391
        10.1177/1078155219856422
        141717391
      ppf: 487
      ppct: 5
      formats:
      tig:
        atl: Ibrutinib-associated sever skin toxicity: A case of multiple inflamed skin lesions and cellulitis in a 68-year-old male patient with relapsed chronic lymphocytic leukemia – Case report and literature review.
      aug:
        au:
          Ghasoub, R
          Albattah, A
          Elazzazy, S
          Alokka, R
          Nemir, A
          Alhijji, I
          Taha, R
        affil: 62850 -->National Center for Cancer Care and Research -->, Hamad Medical Corporation (HMC), Doha, Qatar
      sug:
        subj:
          Recurrence Drug Therapy
          Leukemia, Lymphocytic, Chronic Drug Therapy
          Tyrosine Kinase Inhibitors Adverse Effects
          Cellulitis Chemically Induced
          Lower Extremity Pathology
          Dermatitis Medicamentosa Drug Therapy
          Male
          Aged
          Tyrosine Kinase Inhibitors Administration and Dosage
          Administration, Oral
          Hyperpigmentation
          Pyoderma Chemically Induced
          Biopsy
          Antibiotics Therapeutic Use
          Cellulitis Drug Therapy
          Aged: 65+ years
          Male
      ab: Introduction: Ibrutinib is an oral inhibitor of Bruton's tyrosine kinase that is used for a variety of B cell hematological malignancies. Skin and subcutaneous tissue manifestations have been reported and were witnessed in up to 32% of the patients on ibrutinib. The mechanism in which ibrutinib can cause skin toxicities has been thought due to the inhibition of epidermal growth factor; c-Kit and platelet-derived growth factor receptor). Here, we report a case of an elderly chronic lymphocytic leukemia patient who developed multiple inflamed lesions and lower limb cellulitis in 100 days after initiating ibrutinib therapy. Case report: A 68-year-old male patient with relapsed chronic lymphocytic leukemia was started on ibrutinib 420 mg orally daily following multiple lines of therapy. Three months following ibrutinib, the patient developed multiple hyper pigmented lesions over both forearms then over both thighs; buttocks and lower limbs. The lesions were labeled as ecthyma and cellulitis that started as papules, which progressed to pustules. Management and outcomes: The patient required admission in which he received prolonged course of antibiotics. Biopsy from the wound showed soft tissue fragment infiltrated by acute and chronic inflammatory cells with necrosis; rare foreign body giant cells and granulation tissue formation; suggestive of abscess. Subsequently, ibrutinib was stopped permanently. Discussion: This is the first case description of an ibrutinib-associated sever skin toxicity in Qatar. The provided information regarding the clinical descriptions of toxicity profiles in general and skin-based in particular is valuable information for daily clinical practice, especially when selecting the optimum first-line treatment for the patient.
      pubtype: Academic Journal
      doctype:
        case study
        pictorial
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N